文献速递前列腺癌

晚期前列腺癌伴DNA错配修复基因突变患者的临床特征与治疗结局

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
PubMed 文献 · Eur Urol · 2018-10-15

Mismatch repair (MMR) gene mutations are rare in prostate cancer, and their histological and clinical characteristics are largely unknown.…

要点

  • MMR突变晚期前列腺癌虽侵袭性强,但对激素治疗反应持久。
  • grade group 5或导管内癌组织学特征应提示评估MMR缺陷。
  • PD-1抑制剂在部分MMR突变患者中可见PSA应答。

核心结论

  • MMR基因突变的晚期前列腺癌临床病理特征侵袭性强,但对标准及新型激素治疗敏感,对PD-1抑制剂有 anecdotal 敏感性。

主要发现

  • 中位年龄64岁,75%为grade group 5(Gleason评分9或10),23%有导管内组织学,46%初诊即转移,31%有内脏转移。
  • 46%患者为MSH6突变,73%显示微卫星不稳定,中位肿瘤突变负荷18/Mb(范围3-165突变/Mb)。
  • 初始雄激素剥夺治疗的中位无进展生存期(PFS)为67个月,阿比特龙/恩扎卢胺的中位PFS为26个月。
  • 4例接受PD-1抑制剂的患者中2例在12周时PSA下降≥50%,这4例的中位PFS为9个月。

临床怎么用

  • 对于grade group 5或导管内癌组织学特征的前列腺癌,应考虑评估MMR缺陷。
  • MMR突变晚期前列腺癌患者可优先考虑标准或新型激素治疗。
  • PD-1抑制剂可作为部分MMR突变患者的治疗选择,但需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mismatch repair (MMR) gene mutations are rare in prostate cancer, and their histological and clinical characteristics are largely unknown. We conducted a retrospective study to explore disease characteristics and treatment outcomes of men with metastatic prostate cancer harboring germline and/or somatic MMR mutations detected using clinical-grade genomic assays. Thirteen patients with a deleterious MMR gene mutation were identified. Median age was 64 yr, 75% had grade group 5 (Gleason sum 9 or 10), 23% had intraductal histology, 46% had metastatic disease at initial diagnosis, and 31% had visceral metastases. Most patients (46%) had MSH6 mutations, 73% demonstrated microsatellite instability, and median tumor mutational load was 18/Mb (range, 3-165 mutations/Mb). Surprisingly, responses to standard hormonal therapies were very durable (median progression-free survival [PFS] of 67 mo to initial androgen deprivation and median PFS of 26 mo to abiraterone/enzalutamide). Two of four men receiving PD-1 inhibitors achieved a ≥50% prostate-specific antigen response at 12 wk, with a median PFS duration in these four men of 9 mo. Despite aggressive clinical and pathological features, patients with MMR-mutated advanced prostate cancer appear to have particular sensitivity to hormonal therapies, as well as anecdotal responses to PD-1 inhibitors. Certain histological features (grade group 5, intraductal carcinoma) should prompt evaluation for MMR deficiency. These data are only hypothesis generating. PATIENT SUMMARY: Prostate cancers with mismatch repair gene mutations have aggressive clinical and pathological features; however, these are very sensitive to standard and novel hormonal therapies, and also demonstrate anecdotal sensitivity to PD-1 inhibitors such as pembrolizumab.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. Eur Urol. 2018. PMID: 30337059. doi:10.1016/j.eururo.2018.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。